Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.55 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13562437 | 0.82 | MKNK1 (0.60) | MKNK1MKNK2CHEK2FYNMAP4K4 | |
| SCHEMBL18762209 | 0.80 | ABL1 (0.44) | MKNK1MKNK2FYNNPC1RAB9A | |
| SCHEMBL13561347 | 0.77 | MKNK1 (0.55) | MKNK1MKNK2CHEK2FYNMAP4K4 | |
| SCHEMBL18762208 | 0.77 | PSMB5 (0.46) | USP7NPC1RAB9ASMN1; SMN2ABL1 | |
| SCHEMBL18763003 | 0.75 | DDT (0.49) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19326420 | 0.73 | PARP1 (0.55) | PARP1 | |
| SCHEMBL4520699 | 0.72 | CYP17A1 (0.58) | MKNK1MKNK2CHEK2SMN1; SMN2 | |
| SCHEMBL10243616 | 0.72 | CYP17A1 (0.58) | MKNK1MKNK2CHEK2SMN1; SMN2 | |
| SCHEMBL15730267 | 0.71 | MKNK1 (1.00) | MKNK1MKNK2CHEK2FYNNPC1 | |
| SCHEMBL11157898 | 0.71 | PARP1 (0.52) | CHEK2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751890-B2 | Heteroaryl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170107225-A1 | HETEROARYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107225-A1 | HETEROARYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCD3 | MKNK1 3202/4885MKNK2 3668/4885USP7 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.